HEPA - Hepion announces A.I. platform for drug development

Hepion Pharmaceuticals ([[HEPA]] +1.9%) has rolled out a proprietary artificial intelligence ((AI)), machine learning platform called, AI-POWR, with an aim to identify responders a priori and reduce the need for large sample sizes through study design enrichment.The components of AI-POWR include access to publicly available databases, in-house genomic and multi-omic big data. AI outputs allow for improved response outcomes through enhanced patient selection, biomarker selection and drug target selection.The company intends to use AI-POWR to help identify which patients that will best respond to CRV431, its lead drug candidate for treatment of NASH patients, currently in a Phase 2a trial.

For further details see:

Hepion announces A.I. platform for drug development